November 14-16, 2017
Boston, MA

LinkedIn Icon

Speaker Line-Up

Expand/Collapse

Amanda Enstrom
Associate Director
Aduro Biotech

Day Two

Thursday, November 16, 2017

12.00 | Targeting Patient-Specific Neoantigens using a Personalized, Live-Attenuated Double Deleted Listeria monocytogenes (pLADD) Immunotherapy

John Castle
Executive Director, Translational Medicine
Agenus

Day Two

Thursday, November 16, 2017

12.30 | Exploiting NGS for Clinical Individualized Neoantigen Cancer Vaccines

James Brown
VP, Corporate Development
Aldevron

Day Two

Thursday, November 16, 2017

11.00 | Meeting the Challenges of Personalized Medicine

Jim Johnston
Executive Director, Research
Amgen

Day One

Wednesday, November 15, 2017

09.30 | Neoantigens as Targets in Oncology: A Compelling Case

Charles Nicolette
CSO
Argo Therapeutics

Day One

Wednesday, November 15, 2017

15.00 | Targeting the Broad Spectrum of Patient-Specific Tumor Neoantigens without the Need to Identify Them

Michal Bassani- Sternberg
Director, Immunopeptidomics
CHUV

Day One

Wednesday, November 15, 2017

12.30 | Accelerating the Development of Personalized Cancer Immunotherapy: Mass Spectrometry based Immunopeptidomics

Pamela Carroll
SVP, Immuno- Oncology
Genocea Biosciences

Day One

Wednesday, November 15, 2017

10.00 | Targets Matter: What Decides a Peptide is an Antigen? Software or the Patient’s T Cells?

Roman Yelensky
EVP & CTO
Gritstone Oncology

Day One

Wednesday, November 15, 2017

17.30 | Chairman’s Closing Remarks

09.00 | Chair’s Opening Remarks

May Pidding
Director, Business Development
Ichor Medical Systems

Day Two

Thursday, November 16, 2017

11.00 | Meeting the Challenges of Personalized Medicine

Harpreet Singh
CSO & Co-Founder
Immatics Biotechnologies

Day One

Wednesday, November 15, 2017

14.00 | Discovering Real Neoantigens through the XPRESIDENT® Mass Spectrometry Platform

Ronald Loggers
CEO
ISA Pharmaceuticals

Day Two

Thursday, November 16, 2017

13.00 | Synthetic Long Peptides for Neoantigen-Specific Immunotherapy of Cancer:

Heather Kinkead
Postdoctoral Fellow, Elizabeth Jaffee Lab
Johns Hopkins School of Medicine

Day Two

Thursday, November 16, 2017

14.30 | Turning Up the Heat on Pancreatic Cancer: Overcoming an Immunologically Cold Landscape

Daniel Sommermeyer
Director, TCR II, T-Cell Engineering
Medigene Immunotherapies

David Kaufman
Head, Translational Oncology
Merck

Day One

Wednesday, November 15, 2017

17.00 | Neoantigens as Prognostic and Diagnostic Tools

Alex Rubinsteyn
Researcher, Hammerbacher Lab
Mount Sinai

Day One

Wednesday, November 15, 2017

12.00 | Open Source Tools and Models for Neoantigen Prediction

Eric Lindquist
VP, Pharma Business Development
Natera

Day One

Wednesday, November 15, 2017

16.30 | Personalized Liquid Biopsy and its Biopharma Applications

Marit van Buuren
PhD, Lab Head, Immunology
Neon Therapeutics

Day Two

Thursday, November 16, 2017

09.30 | Neoantigens as Targets for Multiple Therapeutic Approaches

Elisa Scarselli
CSO
Nouscom

Workshop B

Tuesday, November 14 2017

13.00 |
An “Off the Shelf” Vaccine Based on Shared Tumor Neoantigens for Prevention and Treatment of MicroSatellite Instable Cancers

Day Two

Thursday, November 16, 2017

10.00 | Vaccination with Great Ape Derived Adenovectors Encoding for Cancer Neoantigens Shows Potent Synergy with Immunomodulators

Johanna Olweus
Professor, Director, K.G. Jebsen Center for Experimental Immunotherapy
University of Oslo

Workshop A

Tuesday, November 14 2017

09.00 |
Systematic Screening for T-cell and Antibody Targets in Cancer

Richard Chen
CSO
Personalis

Day One

Wednesday, November 15, 2017

14.30 | From Sample to Neoantigens for Vaccines: Key Challenges and Solutions

Donna Nichol
Oncology Science Liaison, Translational Science & Diagnostics
Personal Genome Diagnostics

Day One

Wednesday, November 15, 2017

11.30 | NGS Solutions for Immuno-Oncology

Agnete Fredrickson
CSO
Vaccibody

Day Two

Thursday, November 16, 2017

15.00 | Development of Safe, Efficacious and Cost-Efficient Cancer Neoantigen Vaccines

Martin Bonde
CEO
Vaccibody

Day Two

Thursday, November 16, 2017

15.30 | Chairman’s Closing Remarks

09.00 | Chair’s Opening Remarks

Laurence Cooper
CEO
ZIOPHARM Oncology

Day Two

Thursday, November 16, 2017

10.30 | Neoantigens are the Achilles’ Heel of Cancer